Actively Recruiting
Phase 3 Study Evaluating Dinutuximab Added to Intensive Chemotherapy, Surgery, Stem Cell Transplant, and Radiation for Newly Diagnosed High-Risk Neuroblastoma in Children and Young Adults
Led by National Cancer Institute (NCI) · Updated on 2026-10-30
478
Participants Needed
180
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying how adding dinutuximab to intensive multimodal therapy may affect treatment outcomes in children with newly diagnosed high-risk neuroblastoma. This phase III trial compares standard chemotherapy and surgery to a combination of chemotherapy plus dinutuximab during Induction therapy. The study also evaluates the effects of subsequent treatments including stem cell transplantation, radiation, and immunotherapy, aiming to improve event-free survival and overall survival for these patients. Participants receive multiple cycles of Induction chemotherapy involving drugs such as cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. They are randomly assigned to either standard chemotherapy or chemoimmunotherapy with dinutuximab. After Induction, patients with good tumor response proceed to Consolidation therapy with two autologous stem cell transplants followed by radiation. Those with poor response receive Extended Induction chemoimmunotherapy. The final Post-Consolidation phase includes dinutuximab and isotretinoin treatments to maintain response. Throughout the study, patients undergo various assessments including blood and urine tests, echocardiograms or MUGA scans, bone marrow biopsies, CT, MRI, I-MIBG, and possibly FDG-PET scans. Researchers monitor response to therapy, adverse events, biomarker expression, and quality of life over time. Follow-up visits occur regularly up to 10 years after enrollment to assess long-term outcomes and safety. The primary measure is event-free survival, with additional outcomes including response rates and overall survival.
CONDITIONS
Brief Title
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here